News
AWH
3.327
+1.42%
0.047
ASPIRA WOMEN'S HEALTH INC FILES FOR MIXED SHELF OF UP TO $100 MLN – SEC FILING
Reuters · 3d ago
Weekly Report: what happened at AWH last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at AWH last week (0408-0412)?
Weekly Report · 04/15 12:14
Aspira Women's Health Price Target Maintained With a $3.30/Share by Cantor Fitzgerald
Dow Jones · 04/10 13:41
Cantor Fitzgerald Reiterates Neutral on Aspira Womens Health, Maintains $3.3 Price Target
Benzinga · 04/10 13:32
Press Release: Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid. Aspira's Ova Suite portfolio of risk assessment tests effective June 1, 2024. The company is focused on the development of gynecologic disease diagnostic tools.
Dow Jones · 04/09 12:00
Weekly Report: what happened at AWH last week (0401-0405)?
Weekly Report · 04/08 12:20
Aspira Women's Health files to sell 1.57M shares for holders
Aspira Women's Health files to sell 1.57M shares for holders. The company filed a prospectus related to a proposed resale of about 1. 57M shares by selling stockholders. This prospectus is not an offer to sell these securities. Aspira women's health Inc. (AWH)
Seeking Alpha · 04/05 21:54
Aspira Women's Health Price Target Cut to $3.30/Share From $4.00 by Cantor Fitzgerald
Dow Jones · 04/01 12:36
Aspira Women's Health Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 04/01 12:36
Cantor Fitzgerald Maintains Neutral on Aspira Womens Health, Lowers Price Target to $3.3
Benzinga · 04/01 12:27
Weekly Report: what happened at AWH last week (0325-0329)?
Weekly Report · 04/01 12:16
Aspira Women’s Health GAAP EPS of -$0.30 beats by $0.15, revenue of $2.13M misses by $0.42M
Aspira Women’s Health GAAP EPS of -$0.30 beats by $0.15, revenue of $2.13M misses by $ 0.42M. The company announced its fourth quarter results after the market closed on Tuesday. Aspira women's health now has a market value of $1.1 billion.
Seeking Alpha · 03/28 20:10
AWH Stock Earnings: Aspira Womens Health Beats EPS, Misses Revenue for Q4 2023
Aspira Womens Health reported earnings per share of -30 cents for the fourth quarter of 2023. The company reported revenue of $2.13 million. This was 16.14% worse than the analyst estimate for revenue in the same period of time.
Investorplace · 03/28 15:53
Aspira Women's Health Inc reports results for the quarter ended in December - Earnings Summary
Aspira Women's Health Inc reported a quarterly adjusted loss of 30 cents per share for the quarter ended in December. Revenue fell 1.1% to $2.13 million from the same quarter last year. The company reported a loss of $3.09 million.
Reuters · 03/28 13:31
Aspira Womens Health Q4 EPS $(0.30) Beats $(0.45) Estimate, Sales $2.13M Miss $2.54M Estimate
Aspira Womens Health reported quarterly losses of $0.30 per share. The company also reported quarterly sales of $2.13 million. Aspira beat the analyst consensus estimate by 33.33%. The company is up 45.45 percent in the past week.
Benzinga · 03/28 11:33
*Aspira Women's Health 4Q Loss/Shr 30c >AWH
Dow Jones · 03/28 11:30
*Aspira Women's Health 4Q Rev $2.13M >AWH
Dow Jones · 03/28 11:30
Press Release: Aspira Women's Health Reports -2-
This press release contains forward-looking statements. These statements involve a number of risks and uncertainties. Actual results could differ from those discussed due to known and unknown risks, uncertainties, and other factors. Aspira Women's Health's offering is expected to close in the near future.
Dow Jones · 03/28 11:30
*Aspira Women's Health 4Q Loss $3.1M >AWH
Dow Jones · 03/28 11:30
More
Webull provides a variety of real-time AWH stock news. You can receive the latest news about Aspira Womens Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About AWH
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.